Virtual Drug Development, Inc. Studying Pre-Exposure Antibiotic For Anthrax
Executive Summary
Virtual Drug Development, Inc. is seeking to develop a pre-exposure prophylactic antibiotic for Bacillus anthracis that could serve as an alternative to the current anthrax vaccine.
You may also be interested in...
TAP Spectracef Launch Planned For Early 2001; Prevacid Sales Are $735 Mil.
Abbott is predicting an early 2001 launch for TAP's cephalosporin antibiotic Spectracef, currently under review at FDA.
TAP Spectracef Launch Planned For Early 2001; Prevacid Sales Are $735 Mil.
Abbott is predicting an early 2001 launch for TAP's cephalosporin antibiotic Spectracef, currently under review at FDA.
Bayer Cipro
Ciprofloxacin approved Aug. 30 by FDA for the post-exposure prophylaxis of anthrax. As its Phase IV commitment Bayer will assist federal agencies in analyzing data in the event of an anthrax outbreak. Bayer is in discussions with the Centers for Disease Control & Prevention and the Department of Defense regarding Cipro stockpiling. The new indication will cover Cipro tablets, oral suspension and I.V. formulations